Indications -- HIV Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- HIV

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (80)	2/21/2009 4:10:54 PM
From: Elroy Jetson	Read Replies (1) of 155

I believe GSK will combine IDX899 with the Epivir used in Epzicom, and perhaps add a second RTI inhibitor. The reason is Epivir resistance creates a far less fit virus, so it's continued use is valuable even in patients whose virus is resistance to Epivir. For this reason the Epivir franchise is far from dying, but it does explain why it is being promoted as part of a combo drug - new patent. The Epzicom franchise was never fully alive because of the drug reaction problems associated with Abacavir. Yes, the new tolerance testing will help, but it still make Abaxavir and Ziagen second string medications. Adding another drug is useful in marketing only if the third addition is uniformly tolerated. This is the main selling point of the Atripla containing a slightly modified version of Epivir with Viread, also sold as Truvada, in combination with the more problematic but durable Sustiva. Atripla is a cheap combination, favored by those paying the bills, which has an extremely unfavorable lipid profile. More widely used is the Truvada combo from Atripla in combination with a protease inhibitor like Reyataz another BMY drug, or protease and integrase inhibitor like Isentress. .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next